Analytical and pharmacokinetic studies with 5-chloro-2′-deoxycytidine

Biochemical Pharmacology

Volumn 64, Issue 10, 2002, Pages 1493-1502

  Hale, JodiAnne T ^a   Bigelow, James C ^a   Mathews, Linda A ^a   McCormack, John J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

5 Chloro 2 deoxycytidine; Cytidine deaminase; Pharmacokinetics; Pyrimidine nucleoside metabolism; Radiation sensitization; Tetrahydrouridine

Indexed keywords

5 CHLORODEOXYCYTIDINE; ACETONITRILE; AMMONIUM SULFATE; CLOXURIDINE; CYTIDINE DEAMINASE; CYTIDINE DEAMINASE INHIBITOR; ENZYME INHIBITOR; NSC 371331; PLASMA PROTEIN; SOLVENT; TETRAHYDROURIDINE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BODY FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEAMINATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG URINE LEVEL; ENZYME ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT ABSORPTION; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAMPLING;

ANIMALS; ANTIMETABOLITES; DEOXYCYTIDINE; DRUG STABILITY; MICE; MODELS, ANIMAL; TETRAHYDROURIDINE; TISSUE DISTRIBUTION;

EID: 0037112279     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01413-2     Document Type: Article

References (25)

1. Mitchell J.B., Russo A., Cook J.A., Straus K.L., Glatstein E. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int. J. Radiat. Biol. 56:1989;827-836.
2. Santos O., Perez L.M., Briggle T.V., Boothman D.A., Greer S.B. Radiation, pool size and incorporation studies in mice with 5-chloro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;357-365.
3. Lawrence T.S., Davis M.A. Selective radiosensitization and cytotoxicity of human melanoma cells using halogenated deoxycytidines and tetrahydrouridine. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1243-1246.
4. Perez L.M., Greer S. Sensitization to X-ray by 5-chloro-2′-deoxycytidine co-administered with tetrahydrouridine in several mammalian cell lines and studies of 2′-chloro derivatives. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1523-1527.
5. Russell K.J., Rice G.C., Brown J.M. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine. Cancer Res. 46:1986;2883-2887.
6. Greer S., Schwade J., Marion H.S. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1059-1069.
7. Tomchick R., Saslaw L.D., Waravdekar V.S. Mouse kidney cytidine deaminase. J. Biol. Chem. 243:1968;2534-2537.
8. McCormack J.J., Marquez V.E., Liu P.S., Vistica D.T., Driscoll J.S. Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds. Biochem. Pharmacol. 29:1980;830-832.
9. Voytek P., Beisler J.A., Abbasi M.M., Wolpert-DeFillippes M.K. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine. Cancer Res. 37:1977;1956-1961.
10. Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., Culp H.W. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos. 20:1992;849-855.
11. Greer S., Santos O., Gottlieb C., Schwade J., Marion H.S. 5-Chlorodeoxycytidine a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;505-510.
12. Mekras J.A., Boothman D.A., Greer S.B. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res. 45:1985;5270-5280.
13. Breithaupt H., Pralle H., Eckhardt T., von Hattingberg M., Schick J., Löffler H. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). Cancer. 50:1982;1248-1257.
14. Storniolo A.M., Allerheiligen S.R.V., Pearce H.L. Preclinical pharmacologic, and phase I studies of gemcitabine. Semin. Oncol. 24:1997;S72-S77.
15. Kreis W., Chan K., Budman D.R., Schulman P., Allen S., Weiselberg L., Lichtman S., Henderson V., Freeman J., Deere M., Andreeff M., Vinciguerra V. Effect of tetrahydrouridine on the clinical pharmacology of 1-β-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 48:1988;1337-1342.
16. Kreis W., Woodcock T.M., Gordon C.S., Krakoff I.H. Tetrahydrouridine: physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer Treat. Rep. 61:1977;1347-1353.
17. 4-octadecyl-1-β-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. J. Pharm. Pharmacol. 49:1997;1076-1081.
18. Chandrasekaran B., Capizzi R.L., Kute T., Morgan T., Dimling J. Modulation of the metabolism and pharmacokinetics of 1-β-D-arabinofuranosylcytosine by 1-β-D-arabinofuranosyluracil in leukemic mice. Cancer Res. 49:1989;3259-3266.
19. Driscoll J.S., Marquez V.E., Plowman J., Liu P.S., Kelley J.A., Barchi J.J. Jr. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J. Med. Chem. 34:1991;3280-3284.
20. 3H ]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine Cancer Treat. Rep. 61:1977;395-407.
21. Hoshi A., Iigo M., Kuretani K., Kanai T., Ichino M. Distribution of cyclocytidine in tissues. Chem. Pharm. Bull. Tokyo. 23:1975;725-728.
22. Avraham Y., Grossowicz N., Yashphe J. Purification and characterization of uridine and thymidine phosphorylase from Lactobacillus casei. Biochim. Biophys. Acta. 1040:1990;287-293.
23. Wataya Y., Santi D.W. Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2′-deoxyuridine as substrate. Anal. Biochem. 112:1981;96-98.
24. Nakayama C., Wataya Y., Meyer R.B. Jr., Santi D.V., Saneyoshi M., Ueda T. Thymidine phosphorylase. Substrate specificity for 5-substituted 2′-deoxyuridines. J. Med. Chem. 23:1980;962-964.
25. Krenitsky T.A. Uridine phosphorylase from Escherichia coli: kinetic properties and mechanism. Biochim. Biophys. Acta. 429:1976;352-358.